Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel–FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice von Pernas, Sonia, Gil-Gil, Miguel, de Olza, María Ochoa, Gumà, Anna, Climent, Fina, Petit, Anna, Pla, María Jesús, García-Tejedor, Amparo, López-Ojeda, Ana, Falo, Cati, Fernandez-Otega, Adela, Mesia, Carlos, Pérez-Martin, Francisco Javier, Urruticoechea, Ander, Germà, Josep Ramon

Volltext